In vitro metabolism study of a new nitrosyl ruthenium complex [Ru(NH·NHq)(terpy)NO]3+ nitric oxide donor using rat microsomes

Nitric Oxide - Biology and Chemistry

Volumn 21, Issue 1, 2009, Pages 14-19

  Oliveira, Anderson Rodrigo Moraes de ^a   Fonseca, Patrícia da ^a   Curti, Carlos ^a   da Silva, Roberto Santana ^a   Bonato, Pierina Sueli ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

In vitro metabolism; Nitric oxide; Nitrosyl ruthenium complex

Indexed keywords

NITRIC OXIDE DONOR; RUTHENIUM COMPLEX;

ACCURACY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BIODEGRADATION; BIOTRANSFORMATION; CONTROLLED STUDY; DRUG METABOLISM; FOOD AND DRUG ADMINISTRATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER MICROSOME; LIVER MICROSOME METABOLISM; MALE; MICHAELIS CONSTANT; NONHUMAN; PRIORITY JOURNAL; RAT; VALIDATION PROCESS;

ANIMALS; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CHROMATOGRAPHY, LIQUID; KINETICS; MALE; MICROSOMES, LIVER; NADP; NITRIC OXIDE DONORS; NONLINEAR DYNAMICS; ORGANOMETALLIC COMPOUNDS; RATS; RATS, WISTAR; REPRODUCIBILITY OF RESULTS; RUTHENIUM;

RATTUS;

EID: 67649774280     PISSN: 10898603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.niox.2009.03.003     Document Type: Article

References (35)

1. A.S. Koster, N.J. de Mol, G. Storm, D. van heuven-Nolsen, G. van den Brink, J. Perquin, Introduction to Pharmacogenesis, Faculty of Pharmaceutical Sciences, Utrecht, The Netherlands, 1997.
2. F.C. Lu, Biotransformation of toxicants, in: Basic Toxicology: Fundamentals, Target Organs and Risk Assessment, third ed., Taylor and Francis, Washington, DC, 1996, pp.27-39.
3. Plant N. Strategies for using in vitro screens in drug metabolism. Drug Discovery Today 9 (2004) 328-336
4. Raucy J.L., and Lasker J.M. Isolation of P450 enzymes from human liver. Methods in Enzymology 206 (1991) 577-587
5. Ignarro L.J. Nitric Oxide: Biology and Pathobiology (2000), Academic Press, San Diego
6. Lincoln J., and Burnstock G. Nitric Oxide in Health and Disease (1997), Cambridge University Press, New York
7. Fang F.C. Nitric Oxide and Infection (1999), Kluwer Academic/Plenum Publishers, New York
8. Lancaster Jr. J. Nitric Oxide: Principles and Actions (1996), Academic Press, San Diego
9. Wang P.G., Cai T.B., and Taniguchi N. Nitric Oxide Donors for Pharmaceutical and Biological Applications (2005), Wiley-VCH, Weinheim
10. Wang P.G., Xian M., Tang X., Wu X., Wen Z., Cai T., and Janczuk A.J. Nitric oxide donors: chemical activities and biological applications. Chemical Reviews 102 (2002) 1091-1134
11. Napoli C., and Ignarro L.J. Nitric oxide-releasing drugs. Annual Review of Pharmacology and Toxicology 43 (2003) 97-123
12. +)(terpy)]Cl. Dalton Transactions (2005) 1176-1187
13. -): modulation of the release of NO by the trans-effect. Inorganic Chimica Acta 358 (2005) 2883-2890
14. Bonaventura D., Oliveira F.S., Togniolo V., Tedesco A.C., da Silva R.S., and Bendhack L.M. A macrocyclic nitrosyl ruthenium complex is a NO donor that induces rat aorta relaxation. Nitric Oxide 10 (2004) 83-91
15. Oliveira F.D., Togniolo V., Pupo T.T., Tedesco A.C., and da Silva R.S. Nitrosyl ruthenium complex as nitric oxide delivery agent: synthesis, characterization and photochemical properties. Inorganic Chemistry Communications 7 (2004) 60-164
16. {radical dot} - ruthenium(II) complexes. Inorganic Chemistry Communications 8 (2005) 347-349
17. de Lima R.G., Sauaia M.G., Bonaventura D., Tedesco A.C., Lopez R.F.V., Bendhack L.M., and da Silva R.S. Controlled nitric oxide photo-release from nitro ruthenium complexes: the vasodilator response produced by UV light irradiation. Inorganica Chimica Acta 358 (2005) 2643-2650
18. 3+ complex and its vasodilator activity based on visible light irradiation. Inorganic Chimica Acta 359 (2006) 2543-2549
19. 3+ complexes upon reduction (L = 1-methylimidazole or benzoimidazole). Transition Metal Chemistry 29 (2004) 430-436
20. Ford P.C., and Laverman L.E. Reaction mechanisms relevant to the formation of iron and ruthenium nitric oxide complexes. Coordination Chemistry Reviews 249 (2005) 391-403
21. Toledo J.C., Neto B.D.S.L., and Franco D.W. Mutual effects in the chemical properties of the ruthenium metal center and ancillary ligands upon coordination. Coordination Chemistry Reviews 249 (2005) 419-431
22. Bonaventura D., de Lima R.G., Vercesi J.A., da Silva R.S., and Bendhack L.M. Comparison of the mechanisms underlying the relaxation induced by two nitric oxide donors: sodium nitroprusside and a new ruthenium complex. Vascular Pharmacology 46 (2007) 215-222
23. Rodrigues G.J., Lunardi C.N., G Lima R., X Santos C., M Laurindo F.R., da Silva R.S., and Bendhack L.M. Vitamin C improves the effect of a new nitric oxide donor on the vascular smooth muscle from renal hypertensive rats. Vascular Pharmacology 18 (2008) 176-183
24. Rodrigues G.J., Restini C.B., Lunardi C.N., Moreira J.E., Lima R.G., da Silva R.S., and Bendhack L.M. Caveolae dysfunction contributes to impaired relaxation induced by nitric oxide donor in aorta from renal hypertensive rats. Journal of Pharmacological Experimental Therapeutics 323 (2007) 831-837
25. Guidance for Industry: Bioanalytical Method Validation, Center for Drug Evaluation and Research, United States Food and Drug Administration. Available from: .
26. Lake B.G. In: Snell K., and Mullock B. (Eds). Biochemical Toxicology - A Practical Approach (1987), IRL Press, Oxford, Washington, DC 183-215
27. Cain K., and Skilleter D.N. In: Snell K., and Mullock B. (Eds). Biochemical Toxicology - A Practical Approach (1987), IRL Press, Oxford, Washington 217-254
28. A.R.M. de Oliveira, F. Marquele-Oliveira, D.C.A. Silva de Santana, S. Nikolaou, R.F.V. Lopez, P.S. Bonato, R.S. da Silva, HPLC separation and NMR, QTOF/MS/MS structure elucidation of a prominent nitric oxide donor agent based on an isomeric composition of a nitrosyl ruthenium complex, Inorganic Chemistry Communications, in press, doi: 10.1016/j.inoche.2009.02.001.
29. Shabir G.A. Validation of high-performance liquid chromatography methods for pharmaceutical analysis. Understanding the differences and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopeia and the International Conference on Harmonization. Journal of Chromatography A 987 (2003) 57-66
30. Bressolle F., Bromet-Petit M., and Audran M. Validation of liquid chromatography and gas chromatographic methods. Applications to pharmacokinetics. Journal of Chromatography B 686 (1996) 3-10
31. Porter T.D., and Coon M.J. Cytochrome P-450. Multiplicity of isoforms, substrates, and catalytic and regulatory mechanisms. Journal of Biological Chemistry 266 (1991) 13469-13472
32. Brown C.M., Reisfeld B., and Mayeno A.N. Cytochromes P450: a structure-based summary of biotransformations using representative substrates. Drug Metabolism Reviews 40 (2008) 1-100
33. Lewis D.F.V. Guide to cytochromes P450: structure and function (2001), Taylor and Francis, London
34. Lewis D.F.V. Human cytochromes P450 associated with the phase 1 metabolism of drugs and other xenobiotics: a compilation of substrates and inhibitors of the CYP1, CYP2 and CYP3 families. Current Medicinal Chemistry 10 (2003) 1955-1972
35. Kobayashi K., Urashima K., Shimada N., and Chiba K. Substrate specificity rat cytochrome P450 (CYP) isoforms: screening with cDNA-expressed systems on the rat. Biochemical Pharmacology 63 (2002) 889-896